Onderzoeker
Hendrik Everaert
- Trefwoorden:Geneeskunde
- Disciplines:Nucleaire beeldvorming
Affiliaties
- Medische Beeldvorming (Onderzoeksgroep)
Lid
Vanaf1 jan 2011 → Heden - nucleaire geneeskunde (Departement)
Lid
Vanaf1 jan 2008 → Heden - Ondersteunende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 28 feb 2023 - Ondersteunende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2014 → 20 okt 2022 - Medische Beeldvorming en Fysische Wetenschappen (Departement)
Lid
Vanaf1 mrt 2010 → 31 dec 2013 - Medische Beeldvorming en Fysische Wetenschappen (Departement)
Lid
Vanaf1 okt 2002 → 30 sep 2010
Publicaties
1 - 10 van 31
- Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Auteurs: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.
Pagina's: 1378-1384 - Preoperative Radiotherapy with a Simultaneous Integrated Boost Compared to Chemoradiotherapy for cT3-4 Rectal Cancer(2023)
Auteurs: Benedikt Engels, Antonino De Paoli, Elena Delmastro, Fernando Munoz, Stefano Vagge, Darius Norkus, Hendrik Everaert, Gianna Tabaro, Elisabetta Gariboldi, Umberto Ricardi, et al.
- Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series(2023)
Auteurs: Jens Tijtgat, Evan Maarten Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, A Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, et al.
- Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer?(2022)
Auteurs: Justine Perrin, Karim Farid, Hilde Van Parijs, Olena Gorobets, Vincent Vinh-Hung, Nam P Nguyen, Navid Djassemi, Mark De Ridder, Hendrik Everaert
Pagina's: 287-302 - The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression(2021)
Auteurs: Karolien Vekens, Hendrik Everaert, Bart Neyns, Bart Ilsen, Lore Decoster
Pagina's: 432-440 - Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients(2021)
Auteurs: Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D Windhorst, Frank Van Der Aa, N Harry Hendrikse, et al.
Pagina's: 1097-1105 - Breast cancer preoperative 18FDG-PET, overall survival prognostic separation compared with the lymph node ratio(2021)
Auteurs: Vincent Vinh-Hung, Hendrik Everaert, Olena Gorobets, Hilde Van Parijs, Guy Verfaillie, Marian Vanhoeij, Guy Storme, Christel Fontaine, Jan Lamote, Justine Perrin, et al.
Pagina's: 956-968 - Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma(2021)
Auteurs: Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, et al.
- A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Auteurs: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
- Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome(2021)
Auteurs: Sim Vermeulen, Gil Awada, M Keyaerts, Bart Neyns, Hendrik Everaert
Pagina's: 1630-1640